Prevail Therapeutics Inc

NASDAQ:PRVL  
10.01
-0.14 (-1.38%)
Earnings Announcements

Prevail Therapeutics Reports Third Quarter 2020 Financial Results And Business Highlights

Published: 11/13/2020 12:20 GMT
Prevail Therapeutics Inc (PRVL) - Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights.
Q3 Loss per Share $0.55.
Q3 Earnings per Share Estimate $-0.65 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.65

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.63

More details on our Analysts Page.